Here's What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results delivered the familiar top and bottom line beat. The firm also stated that Trikafta revenue came in slightly below consensus and Alyftrek slightly above. The same day, Barclays also adjusted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $607 from $606 and maintained an Overweight rating on the shares after the fiscal Q4 report.

In another development, H.C. Wainwright lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $591 from $518 on February 17, reaffirming a Buy rating on the shares and stating that it views povetacicept as “the best-in-class contender” in primary membranous nephropathy following Roche’s Phase 3 MAJESTY study.

The rating updates came after Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its fiscal Q4 and full year 2025 earnings on February 12, reporting a full year total revenue of $12.0 billion, reflecting a 9% growth compared to full year 2024. Total revenue for fiscal Q4 came up to $3.19 billion, up 10% compared to the prior year period.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops medicines for rare, serious diseases. The company’s product pipeline includes clinical-stage programs for various disorders, including TDT, SCD, CF, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency.